AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial

October 13, 2026 3:15 PM

AbbVie (NYSE: ABBV) presented new data from its Phase 3 AFFIRM study at the American College of Gastroenterology 2026 Annual ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found